VIMOVO
País: Israel
Idioma: anglès
Font: Ministry of Health
Alguns documents d’aquest producte actualment no estan disponibles, podeu enviar una sol·licitud al nostre servei d’atenció al client i us ho notificarem tan bon punt puguem obtenir-los.
Enviar sol.licitud.
Enviar sol.licitud.
ingredients actius:
ESOMEPRAZOLE AS MAGNESIUM TRIHYDRATE 20 MG; NAPROXEN 500 MG
Disponible des:
ASTRA ZENECA ISRAEL LTD
Codi ATC:
G02CC02
formulario farmacéutico:
TABLETS MODIFIED RELEASE
Vía de administración:
PER OS
Fabricat per:
ASTRA ZENECA AB., SWEDEN
Grupo terapéutico:
NAPROXEN
indicaciones terapéuticas:
Vimovo is a combination product that contains naproxen and esomeprazole. It is indicated for the relief of signs and symptoms of osteoarthritis, rheumatoid arthritis and ankylosing spondylitis and to decrease the risk of developing gastric ulcers in patients at risk of developing NSAID-associated gastric ulcers.Vimovo is not recommended for initial treatment of acute pain because the absorption of naproxen is delayed compared to absorption from other naproxen-containing products.
Data d'autorització:
2011-12-01
